Skip Navigation

Cardiovascular Research 2005 66(3):543-551; doi:10.1016/j.cardiores.2005.02.006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Iwase, T.
Right arrow Articles by Kitamura, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwase, T.
Right arrow Articles by Kitamura, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia

Takashi Iwasea,b, Noritoshi Nagayaa,*, Takafumi Fujiic, Takefumi Itoha, Shinsuke Murakamia, Toshio Matsumotob, Kenji Kangawad and Soichiro Kitamurae

aDepartment of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
bDepartment of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan
cDepartment of Cardiac Physiology, National Cardiovascular Center Research Institute, Osaka, Japan
dDepartment of Biochemistry, National Cardiovascular Center Research Institute, Osaka, Japan
eDepartment of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan

* Corresponding author. Tel.: +81 6 6833 5012; fax: +81 6 6833 9865. Email address: nnagaya{at}ri.ncvc.go.jp

Objective: Mesenchymal stem cells (MSC) are pluripotent cells that differentiate into a variety of cells including endothelial cells and vascular smooth muscle cells. Although transplantation of bone marrow-derived mononuclear cells (MNC) has already been applied for the treatment of critical limb ischemia, little information is available regarding comparison of the angiogenic potency between MSC and MNC. Accordingly, we injected equal numbers of MSC or MNC in a rat model of hindlimb ischemia and compared their therapeutic potential.

Methods and results: Immediately after creating hindlimb ischemia, rats were randomized to receive MSC transplantation (MSC group), MNC transplantation (MNC group), or vehicle infusion (Control group). Three weeks after transplantation, the laser Doppler perfusion index was significantly higher in the MNC group than in the Control group (0.69 ± 0.1 vs. 0.57 ± 0.06, P<0.01). Furthermore, there was a marked improvement in blood perfusion in the MSC group (0.81 ± 0.08). Capillary density was highest in the MSC group. The number of transplanted cell-derived endothelial cells was higher in the MSC group than in the MNC group. Transplanted cell-derived vascular smooth muscle cells were detected only in the MSC group. In vitro, MSC were more tolerant to apoptotic stimulus (serum starvation and hypoxia) than MNC.

Conclusions: MSC transplantation caused significantly greater improvement in hindlimb ischemia than MNC transplantation. Compared with MNC, MSC survived well under an ischemic environment, and differentiated into not only endothelial cells but also vascular smooth muscle cells. Thus, MSC transplantation may be a new therapeutic strategy for the treatment of severe peripheral vascular disease.

KEYWORDS Angiogenesis; Apoptosis; Cell therapy

Time for primary review 19 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
T. Shibata, K. Naruse, H. Kamiya, M. Kozakae, M. Kondo, Y. Yasuda, N. Nakamura, K. Ota, T. Tosaki, T. Matsuki, et al.
Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells Improves Diabetic Polyneuropathy in Rats
Diabetes, November 1, 2008; 57(11): 3099 - 3107.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. R. Ward and D. J. Stewart
Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three?
Cardiovasc Res, August 1, 2008; 79(3): 357 - 359.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S.-W. Cho, I.-K. Kim, S. H. Bhang, B. Joung, Y. J. Kim, K. J. Yoo, Y.-S. Yang, C. Y. Choi, and B.-S. Kim
Combined therapy with human cord blood cell transplantation and basic fibroblast growth factor delivery for treatment of myocardial infarction
Eur J Heart Fail, October 1, 2007; 9(10): 974 - 985.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. M. Piper and E. A. Martinson
Cardiovascular Research speeds up-Even more
Cardiovasc Res, March 1, 2006; 69(4): 773 - 776.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Napoli, S. Williams-Ignarro, F. de Nigris, G. de Rosa, L. O. Lerman, B. Farzati, A. Matarazzo, G. Sica, C. Botti, A. Fiore, et al.
Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb
PNAS, November 22, 2005; 102(47): 17202 - 17206.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.